Troy Hamilton, Pharm.D.

Chief Executive Officer

Troy Hamilton is Chief Executive Officer of Synergy. Troy has over 21 years of experience in the pharmaceutical industry, with an emphasis on general management, commercialization, partnerships, acquisitions, and global product launches in the gastroenterology and primary care markets. Previously, Troy served as Chief Commercial Officer of Synergy from July 2015 to December 2017. Prior to joining Synergy, Troy held multiple commercial leadership roles over a nine year period within the Gastrointestinal (GI) Business Unit at Shire Pharmaceuticals, including Vice President, Product Strategy and Commercial Lead, Vice President of GI International Marketing, Global General Manager for the Inflammatory Bowel Disease franchise, and Head of US Marketing. Before Shire, he spent 10 years at Johnson & Johnson's Janssen Pharmaceuticals and McNeil Specialty Products in a number of in-house and field-based leadership roles within brand management, strategic planning, new product development, and medical services. Troy holds a BSc in Pharmacy and PharmD from the University of the Sciences in Philadelphia and an MBA from St. Joseph's University.

Patrick H. Griffin, M.D., FACP

Executive Vice President and Chief Medical Officer

Patrick Griffin, M.D., is a board-certified physician in both internal medicine and gastroenterology, and is a Fellow of the American College of Physicians. He received his medical degree from Columbia University, completing a residency in internal medicine at Presbyterian Hospital in New York, and a fellowship in gastroenterology at Brigham and Women's Hospital in Boston. Following his residency and fellowship, Dr. Griffin joined the medical faculty of Columbia College of Physicians and Surgeons, where he held a number of academic, clinical research, teaching and management positions, as well as a solo private practice in New York. He subsequently moved to the biopharmaceutical industry, where he held positions of increasing responsibility, first at Forest Laboratories, and subsequently at Sanofi-Aventis, culminating with his appointment as Associate Vice-President, Clinical Development.

Marino Garcia

Executive Vice President and Chief Strategy Officer

Mr. Garcia, M.B.A, has over 22 years of experience in various commercial, new product planning and business development roles. Prior to joining Synergy in March 2014, he served as Vice President of Global Business Development at Aptalis Pharma, a privately held specialty company focused on the gastrointestinal and cystic fibrosis markets which was acquired by Forest Labs in early 2014. From 2006 to 2010, he served as Vice President of US Commercial Operations and New Product Development at Aspreva Pharmaceuticals, which was acquired by Zurich-based Vifor Pharmaceuticals. Earlier in his career, he served in various U.S. and international leadership roles of increasing responsibility in companies like Eli Lilly & Co and Pfizer.

Mr. Garcia received a Bachelor's Degree in Business Administration from Concordia University in Montreal, Quebec, and an M.B.A. from the Ivey Business School at Western University in London, Ontario.

Gary G. Gemignani

Executive Vice President and Chief Financial Officer

Mr. Gemignani’s career in healthcare spans over three decades, including senior management positions at several pharmaceutical and biopharmaceutical companies. Most recently, he served as Chief Executive Officer and Chief Financial Officer of Biodel, Inc., (now Albireo), overseeing business and strategic planning, operations, and financing activities of the Company. During his tenure, Mr. Gemignani successfully led the reverse merger with Albireo and managed several corporate restructurings to strengthen Albireo’s overall financial position. Prior to this role, Mr. Gemignani served in senior and executive financial and operational roles with multiple public and private companies including Coronado Biosciences, Inc., Gentium S.p.A., Novartis Pharmaceutical Corp. and Wyeth. Mr. Gemignani began his career with Arthur Andersen and Company and holds a Bachelor’s of Science from St. Peter’s College.

Chhaya Shah

Senior Vice President, Manufacturing & Technical Operations

Chhaya Shah joins Synergy with more than 25 years of experience in the pharmaceutical industry, with expertise in end-to-end supply chain for commercially marketed and development products, quality assurance, CMC and manufacturing. Prior to joining Synergy, from September 2013 to December 2015, she served as Vice President, Technical Operations, Business Unit Partnership of Shire Pharmaceuticals. she was responsible for end-to-end supply chain for 23 commercially marketed products and 15 development products. From November 2008 to September 2013, she served as Senior Director, Global Supply Chain for GI Division of Shire, and from November 2004 to October 2008 she served as Director, Corporate Quality Assurance—Compliance Division of Shire. In this role she developed Quality Systems for Shire and accomplished approval of multiple products globally including PAI inspections. Prior to joining Shire Pharmaceuticals, she served as Compliance Director—Quality Assurance at Wyeth Pharmaceuticals, Vaccine Division. Prior to that, she served in a variety of roles with Abbott Laboratories, including leading a manufacturing site.

Ms. Shah earned a B.S. in Electrical Engineering from Wilkes University. She is a Certified Quality Engineer and Certified Quality Manager and holds a Lean Six Sigma Green Belt.

Dan Dunham, J.D.

Senior Vice President and Chief Compliance Officer

After consulting with the Company for one year, Dan Dunham, J.D., joined Synergy as our Senior Vice President and Chief Compliance Officer in March 2017.  Mr. Dunham has been responsible for building the Company’s corporate compliance program in concert with the commercialization of our first product.  Prior to joining us, Mr. Dunham served as Chief Compliance Officer at Astellas U.S. LLC, Aptalis Pharma US, Inc. and Health Diagnostic Laboratory, Inc.  In this capacity, he inaugurated compliance departments and programs, successfully defended government investigations and negotiated and then secured compliance with a Corporate Integrity Agreement. 

In the mid-1990s, Mr. Dunham created the pharmaceutical industry’s first modern compliance program at Warner-Lambert Company.  Also at Warner-Lambert, Mr. Dunham defended one of the first criminal prosecutions of an ethical pharmaceutical company, helped lead the company’s efforts to comply with a manufacturing and laboratory-focused consent decree and defended one of the industry’s first modern off-label promotion prosecutions.  Subsequently, at Pharmacia Corporation and Pfizer Inc., Mr. Dunham defended Medicaid and Medicare “AWP” pricing fraud cases.

Mr. Dunham graduated summa cum laude with a Bachelor of Arts degree from the University of South Dakota in 1974 and received his law degree from Columbia University in 1978.  Prior to joining the pharmaceutical industry, Mr. Dunham practiced law in New York, New York, specializing in commercial litigation.

Marianne Jackson

Senior Vice President, Sales & Market Access

Marianne joins Synergy with over 25 years of commercial leadership experience in the biopharmaceutical industry with emphasis on P&L and general management, strategy, product launches, brand marketing, sales, commercial operations and market access. She has worked extensively in both US and international markets in the gastrointestinal, CNS, pain and rare disease therapeutic areas. Most recently, Marianne held the role of SVP of Global Commercial operations at Shire Pharmaceuticals where she was responsible for building and leading the market insight, sales force effectiveness and training, marketing services and commercial compliance operations teams to support the $6 billion business. Prior to that, she was the VP of Sales for the GI Business Unit at Shire and was instrumental in guiding the flagship brand, Lialda®, to a market leadership status. Prior to Shire, Marianne spent over 20 years at AstraZeneca in various leadership roles encompassing VP of Global Marketing, National Sales Director, Area Sales Director and she led the marketing efforts for brands such as Vimovo®, Seroquel®, Nexium® and Prilosec®.  

Marianne received her BBA in Marketing and Master of Science degrees from Texas A&M University. She is an active member of the National MS Society, where she was previous Board Chair of the Greater Delaware Valley chapter.

Leslie Magnus, M.D.

Senior Vice President, Medical Affairs

Leslie Magnus, M.D., joins Synergy with over 25 years of experience in the pharmaceutical industry, with expertise in building and leading Medical Affairs teams (Medical Science Liaisons, Scientific Communications, Medical Information, Pharmacovigilance).  Her background includes work in multiple therapeutic areas including gastroenterology, women’s healthcare, neuroscience and neuropathic pain for both launch products as well as established brands.  In addition, she has significant experience in clinical research.

Prior to joining Synergy, Dr. Magnus held positions at both large and small pharmaceutical organizations including Allergan, Parke-Davis/Warner Lambert, UCB and Aspreva.  At these organizations, Dr. Magnus worked on compounds such as Neurontin, Loestrin, Keppra and several gastrointestinal products.

She received her undergraduate degree from Brown University, her medical degree from Albany

Medical College and completed her residency training at New York Hospital-Cornell Medical Center.  She is an author on numerous scientific publications.

Pam Cebulski

Senior Vice President, Marketing

Pamela joins Synergy with more than 25 years of healthcare experience, with a strong background in several US and global commercial-related areas including new product development, product launches, P&L responsibility, sales & marketing leadership, partnerships, and acquisitions. This experience spans numerous healthcare markets including gastroenterology, neuroscience, pain, respiratory care and women’s health.   

Prior to Synergy, Pam had an extensive career with Johnson & Johnson spanning all three business sectors of consumer, pharmaceuticals and medical devices. Most recently, she was responsible for the Ethicon Advanced Biologics franchise as well as medical device innovation with a focus in the colorectal specialty. Prior to this position, she held several positions at Janssen Pharmaceuticals leading the Invega® Sustenna®, Invega®, Risperdal® Consta®, Topamax®, Aciphex®, and Duragesic® marketing teams.   

Pam’s career at Johnson & Johnson began in the Consumer Sector where she progressed through roles of increasing responsibility across OTC and consumer products companies leading notable brands such as Tylenol, Imodium A-D, Stayfree, Carefree, o.b., Monistat, K-Y, Healthy Woman, Uristat, Nizoral Rx-to-OTC switch and the Aveeno acquisition. 

Pam’s career in brand management began with Procter & Gamble in the respiratory care OTC franchise. She earned her MBA from Cornell University’s Johnson Graduate School of Management and BS in Marketing/International Business from The American University.

Scott Brunetto

Vice President, Commercial Operations

Scott joins Synergy with over 25 years of experience in the pharmaceutical industry, with an emphasis on marketing and sales analytics including marketing research, forecasting, competitive intelligence, promotion response modeling, sales force analysis and incentive compensation. He has experience across multiple in-line Rx and OTC brands as well as experience with commercialization, partnerships, acquisitions, and global product launches in gastroenterology and other specialty markets.  

Prior to joining Synergy, Scott held business intelligence and commercial operation leadership roles over a seven-year period within Shire Pharmaceuticals' GI Business Unit. Most recently, he was Senior Director, Global Commercial Insights & Analytics, responsible for the Shire’s global GI portfolio. He joined Shire as the Head of Global Market Research for the GI Business Unit, working on recently launched Lialda® and the continued commercialization of Pentasa®. 

He previously spent 14 years at Johnson & Johnson's Janssen Pharmaceuticals, McNeil Specialty Products, and Ortho-McNeil in several commercial operations and analytic leadership roles across a number of therapeutic areas including mycology, allergy, CNS, pain, and women’s health. He came to J&J from IMS Health.

Scott holds a BBA in Marketing from the George Washington University School of Business.